We read with interest the recent article published by Bryant et al, in which they report the first case of isolated pulmonary Kaposi's sarcoma (KS) in a pregnant patient. 1 The authors correctly point out the increasing incidence of KS reported in women, particularly in Africa, and also that HIV-infected women afflicted with KS appear to follow a more aggressive and often fatal course. However, they did not mention two very interesting points regarding KS in pregnancy.First, although the infant in the paper reported by Bryant et al remained HIV and HHV-8 negative, KS has been documented in infants, 2-3 demonstrating the potential for vertical transmission of this neoplasm. In an intriguing and related paper, investigators studying recipients of renal transplants proved that KS cells from organ donors may indeed enter the blood circulation and thereby contribute to the development of post-transplant KS. 4 Second, the authors did not discuss why KS in some pregnant individuals has been reported to undergo spontaneous remission. 5 In nude mice the inhibition of KS during early pregnancy, when chorionic gonadotropin-like activity is maximal, has also been shown. 6 These findings are in keeping with recent experiments showing that urinary preparations of human chorionic gonadotropin (hCG) are capable of inducing apoptosis in KS cells, 7 and exhibit the ability to inhibit KS-associated angiogenesis and matrix metalloprotease activity. 8,9 Bryant's case of pulmonary KS in a pregnant woman is particularly noteworthy given the aforementioned anti-KS properties of hCG, but is in line with a study of African HIV-infected women, in which pregnancy was not associated with lower KS rates. 10 Further investigations are warranted to elucidate the interplay between pregnancy and KS, as well as the potential benefit of hCG as an anti-KS therapeutic.